The heterogeneity of psychiatric disorders and the lack of reliable biomarkers for prediction
and treatments follow-up pose difficulties towards recognition and understanding of the …

Treatment-resistant schizophrenia (TRS) often results in severe disability and functional
impairment. Currently, the diagnosis of TRS is largely exclusionary and emphasizes the …

Opioids are employed in the management of chemotherapy-induced neuropathic pain
(CINP) when other pain management approaches have failed and proven ineffective …

Vascular cognitive impairment (VCI) due to chronic cerebral hypoperfusion (CCH), is the
second leading cause of dementia. Although synaptic impairment plays a critical role in VCI …

Treatment-resistant schizophrenia (TRS) is often associated with severe burden of disease,
poor quality of life and functional impairment. Clozapine is the gold standard for the …

microRNA-218 (miR-218) has been linked to several cognition related neurodegenerative
and neuropsychiatric disorders. However, whether miR-218 plays a direct role in cognitive …

MiRNAs are emerging as key molecules to study neuropsychiatric diseases. However,
despite the large number of methodologies and software for miRNA-seq analyses, there is …

Earlier studies have revealed microRNAs (miRNAs) as potential biomarkers for neurological
conditions, however, such evidence on psychiatric outcomes is limited. We utilized the …

Schizophrenia is a serious mental disease that is regulated by multiple genes and
influenced by multiple factors. Due to the complexity of its etiology, the pathogenesis is still …

To investigate the clinical application value of pharmacogenetic testing in individualized
drug therapy for adult male patients with schizophrenia. A total of 186 adult patients with …